Caroline Loew - 07 Jul 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Role
Chief Executive Officer, Director
Signature
/s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew
Issuer symbol
MURA
Transactions as of
07 Jul 2025
Net transactions value
-$30,475
Form type
4
Filing time
09 Jul 2025, 17:00:03 UTC
Previous filing
05 Mar 2025
Next filing
05 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Loew Caroline Chief Executive Officer, Director C/O MURAL ONCOLOGY PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND /s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew 09 Jul 2025 0001989488

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MURA Ordinary Shares Sale $30,475 -12,531 -4.1% $2.43 293,059 07 Jul 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on March 27, 2024, and the sale does not represent a discretionary trade by the Reporting Person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.53. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 220,148 restricted stock units.